World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
71
Citations
27499
World Ranking
2272
National Ranking
1101

Medicine

D-Index
71
Citations
27499
World Ranking
19936
National Ranking
9928

Mark B. Feinberg publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark B. Feinberg sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 149 publications — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark B. Feinberg D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark B. Feinberg sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 71 D-Index — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mark B. Feinberg is affiliated with the International AIDS Vaccine Initiative in the United States. Their research primarily focuses on medicine, immunology and microbiology, and biochemistry, genetics, and molecular biology. A significant portion of their work falls under the subfields of infectious diseases, molecular biology, immunology, virology, and genetics.

The scientist's main topics of research include:

  • SARS-CoV-2 and COVID-19 Research
  • HIV Research and Treatment
  • Viral Infections and Outbreaks Research
  • Virus-based gene therapy research
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing
  • Immunotherapy and Immune Responses

Their recent papers reflect a focus on vaccine development, immunogenicity, and antibody production related to COVID-19 and HIV. Notable publications include:

  • "A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates," 2023, Nature Communications
  • "Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools," 2021, Biotechnology and Bioengineering
  • "Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera," 2022, EBioMedicine
  • "Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth," 2020, Vaccines
  • "A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates," 2022, bioRxiv (Cold Spring Harbor Laboratory)

The scientist's frequent coauthors include Payton A. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, and Prabhu S. Arunachalam. These collaborations have contributed to multiple publications across various respected venues.

Publication venues that frequently feature the scientist's work include Nature Communications, EBioMedicine, bioRxiv (Cold Spring Harbor Laboratory), Vaccines, and Biotechnology and Bioengineering.

Best Publications

  • Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents

    A. S. Fauci;J. G. Bartlett;E. P. Goosby;M. D. Smith

  • Changes in thymic function with age and during the treatment of HIV infection

    Daniel C. Douek;Richard D. McFarland;Phillip H. Keiser;Earl A. Gage

  • The trans-activator gene of HTLV-III is essential for virus replication

    Fisher Ag;Feinberg Mb;Josephs Sf;Harper Me

  • Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus

    Joseph M. McCune;Linda B. Rabin;Mark B. Feinberg;Miriam Lieberman

  • HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA

    Mark B. Feinberg;Ruth F. Jarrett;Anna Aldovini;Robert C. Gallo

  • Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

    Guido Silvestri;Donald L. Sodora;Richard A. Koup;Richard A. Koup;Mirko Paiardini

  • Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.

    Jeffrey D. Lifson;Jeffrey D. Lifson;Mark B. Feinberg;Gregory R. Reyes;Linda Rabin

  • The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.

    M D Miller;M T Warmerdam;I Gaston;W C Greene

  • Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

    Joseph D. Miller;Robbert G. van der Most;Rama S. Akondy;John T. Glidewell

  • Regulation of the human interleukin-2 receptor α chain promoter: Activation of a nonfunctional promoter by the transactivator gene of HTLV-I

    Sharon L Cross;Mark B Feinberg;Julie B Wolf;Nikki J Holbrook

  • Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I

    M Siekevitz;M B Feinberg;N Holbrook;F Wong-Staal

  • Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency.

    Roger J. Pomerantz;Roger J. Pomerantz;Didier Trono;Mark B. Feinberg;David Baltimore

  • The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.

    Mark B. Feinberg;David Baltimore;Alan D. Frankel

  • Multiple sclerosis and human T-cell lymphotropic retroviruses.

    Hilary Koprowski;Elaine C. DeFreitas;Mary E. Harper;Magnhild Sandberg-Wollheim

  • Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.

    T Harrer;E Harrer;S A Kalams;P Barbosa

  • HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus

    Didier Trono;Mark B. Feinberg;David Baltimore

  • Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections

    Judith N Mandl;Ashley P Barry;Thomas H Vanderford;Natalia Kozyr

  • Strong Cytotoxic T Cell and Weak Neutralizing Antibody Responses in a Subset of Persons with Stable Nonprogressing HIV Type 1 Infection

    Thomas Harrer;Ellen Harrer;Spyros A. Kalams;Tarek Elbeik

  • ACTIVATION OF VIRUS REPLICATION AFTER VACCINATION OF HIV-1-INFECTED INDIVIDUALS

    S I Staprans;B L Hamilton;S E Follansbee;T Elbeik

  • AIDS vaccine models: challenging challenge viruses.

    Mark B Feinberg;John P Moore

Frequent Co-Authors

Guido Silvestri
Guido Silvestri Emory University
Raul Andino
Raul Andino University of California, San Francisco
David Baltimore
David Baltimore California Institute of Technology
Silvija I. Staprans
Silvija I. Staprans Bill & Melinda Gates Foundation
Ann Chahroudi
Ann Chahroudi Emory University
Flossie Wong-Staal
Flossie Wong-Staal University of California, San Diego
Bruce D. Walker
Bruce D. Walker Harvard University
Robert C. Gallo
Robert C. Gallo University of South Florida
Warner C. Greene
Warner C. Greene University of California, San Francisco
John D. Altman
John D. Altman Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA can open doors to various online degree programs and career pathways, especially within healthcare and nursing fields. For those interested in advancing clinical expertise, exploring dnp salary by specialty can help identify the financial benefits tied to different areas of nursing practice, including immunology-related roles.

Nurses aiming to specialize further might consider transitioning certifications, such as moving from a Family Nurse Practitioner to an acute care setting. The insights found in fnp to acute care certification highlight key steps and requirements for this path, which complements immunology-focused patient care in acute or critical settings.

Accelerated options are also available for busy professionals. Those looking for fast-tracked education may benefit from accelerated np programs online, which help candidates quickly gain advanced credentials necessary for immunology-related advanced practice roles.

For newcomers without nursing backgrounds, foundational programs like the best online bsn programs for non nurses offer accessible routes to enter the field, creating pathways toward immunology and related healthcare careers.

Best Scientists Citing Mark B. Feinberg

Trending Scientists

Recently Published Articles